title: Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute.
abstract: This study was undertaken to reveal the trends of prostate cancer and the outcome of treatment modalities for each disease stage in patients in a single institute over a 10-year period. From January 1994 through December 2003, 420 consecutive patients with previously untreated and histologically confirmed prostate cancer were analyzed for annual distributions of disease stages and treatment modalities and for long-term clinical progression-free survival, prostate cancer-specific survival, and prostate-specific antigen (PSA) failure-free survival rates for each stage and treatment modality. Annual trends showed that the number of patients, especially those with clinically localized cancer, increased dramatically. The 5-year disease-specific survival rates for patients with clinically localized disease were 100 percent for all treatment modalities, including hormonal therapy alone. Patients with PSA levels less than 10 ng/ml showed an 81 percent 5-year PSA failure-free survival rate with radical prostatectomy. Stage C patients treated by surgery or radiation-based therapy with concomitant hormonal therapy obtained 93 percent and 100 percent cause-specific survival rates, respectively, and those treated by hormonal therapy alone showed a 79 percent rate. The number of patients with localized prostate cancer was increasing in this decade. While long-term hormonal therapy alone was highly efficient in controlling localized prostate cancer, radical therapies in conjunction with neo-adjuvant hormonal therapy produced better survival rates in cases of locally advanced disease.
authors.affiliation: Department of Urology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan.
authors.forename: Kohei
authors.initials: K
authors.lastname: Edamura
authors.forename: Takashi
authors.initials: T
authors.lastname: Saika
authors.forename: Takashi
authors.initials: T
authors.lastname: Senoh
authors.forename: Fumihito
authors.initials: F
authors.lastname: Koizumi
authors.forename: Daisuke
authors.initials: D
authors.lastname: Manabe
authors.forename: Shin
authors.initials: S
authors.lastname: Ebara
authors.forename: Haruki
authors.initials: H
authors.lastname: Kaku
authors.forename: Teruhiko
authors.initials: T
authors.lastname: Yokoyama
authors.forename: Fernando
authors.initials: F
authors.lastname: Abarzua
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nagai
authors.forename: Yasutomo
authors.initials: Y
authors.lastname: Nasu
authors.forename: Tomoyasu
authors.initials: T
authors.lastname: Tsushima
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kumon
mesh_terms: D000047:Academies and Institutes; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017063:Outcome Assessment, Health Care; D011471:Prostatic Neoplasms / Q000473:pathology / Q000601:surgery* / Q000628:therapy*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome